Key Takeaways Patients and doctors are disagreeing about sleep apnea treatment Doctors favor the use of CPAP machines But patients with obesity would rather use Zepbound to ease their apnea MONDAY ...

But Zepbound is only for people with obesity and sleep apnea, the society noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss, but might not cure the problem.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

FDA approval for Zepbound in treating sleep apnea was based on two previous Eli Lilly-sponsored trials published in the New England Journal of Medicine involving nearly 470 participants, some of ...

According to Eli Lilly, after one year, 42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic obstructive sleep apnea, compared to ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the ...

The Food and Drug Administration has authorized the use of Zepbound for adults with obesity and moderate to severe obstructive sleep apnea. Updated December 22, 2024 at 17:10 PM ET ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.